moneywork4me : Hat MGEN Tenbagger-Potential?
Wedbush analyst Liana Moussatos reiterated a Buy rating on Miragen Therapeutics Inc (MGEN ? Research Report) today and set a price target of $24. The company?s shares opened today at $2.80, close to its 52-week low of $2.20.
According to TipRanks.com, Moussatos ? ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.8% and a 35.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
Miragen Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $18, representing a 542.9% upside. In a report issued on May 9, Oppenheimer also reiterated a Buy rating on the stock with a $12 price target.
Über Miragen: http://www.miragen.com/